Decentralized CoordinationFederationmedium
Federated Pembrolizumab Biosimilar Network
After exclusivity weakens, pembrolizumab pressure could come from a federation of qualified regional biologics manufacturers that share validated process packages, procurement commitments, and post-market evidence instead of relying on a single global brand owner. The disruptive move is not open chemistry in the abstract; it is reducing the market’s dependence on one concentrated commercial and manufacturing stack for a therapy class that already has huge clinical demand.
Thesis
This would shift market power from one branded immunotherapy franchise toward multiple regulated suppliers coordinated through shared standards, pooled procurement, and biosimilar pathways.
Bitcoin / decentralization role
The relevant decentralization is federated manufacturing and procurement, not Bitcoin. Trust moves from a single incumbent brand toward a network of regulators, reference standards, batch-release systems, and regional producers.
Coordination mechanism
Public buyers, oncology networks, and payers aggregate demand; qualified manufacturers obtain licenses or enter post-exclusivity biosimilar development; shared analytical packages and pooled post-market surveillance reduce duplication across regions.
Verification / trust model
Trust depends on regulator-reviewed comparability, GMP inspections, validated analytics, lot release, serialized supply-chain tracking, and pharmacovigilance. Cheating is constrained by batch testing, inspection, and the legal liability attached to biologic manufacturing, though comparability remains expensive and technically demanding.
Failure modes
- • Analytical and clinical comparability for a complex biologic may remain too expensive for many regional suppliers.
- • Manufacturing fragmentation can fail if demand is not large enough to sustain multiple compliant plants.
- • Freedom-to-operate and know-how barriers can delay entry even after headline exclusivity pressure increases.
Adoption path
- • Simplified biosimilar rules and shared public procurement lower the cost of first entrants.
- • One or two regional manufacturers prove reliable supply and comparability, then additional buyers standardize them into formularies.
Decentralization fit
6.0/10
A federated biosimilar market is structurally plausible because biologics supply does not need to remain tied to a single brand owner forever, but the model still relies on regulated manufacturers rather than peer-to-peer end users.
Coordination credibility
6.0/10
Pooled procurement, biosimilar regulation, and voluntary licensing are established coordination tools, though building a functioning multi-region network for an oncology biologic remains operationally heavy.
Implementation feasibility
4.0/10
Biologics manufacturing, comparability, and regulatory approval remain hard, and KEYTRUDA’s current franchise strength shows the incumbent still controls the category economically.
Incumbent pressure
7.0/10
Because KEYTRUDA contributes such a large share of Merck’s revenue, even partial biosimilar or licensing pressure would matter materially to Merck’s earnings mix.
Sources
Merck Announces Fourth-Quarter and Full-Year 2025 Financial ResultsMerck Quarterly Report on Form 10-Q for the quarter ended September 30, 2025FDA Moves to Accelerate Biosimilar Development and Lower Drug CostsAbout Advanced Manufacturing for Public Health Emergency Preparedness and ResponseImproving Access to BiotherapeuticsKEYTRUDA Official Site